Firms Should Look To Local CROs For Clinical Trials in Asia
This article was originally published in PharmAsia News
When conducting clinical trials in Asia, it may be more advantageous for firms to do business with locally-owned contract research organizations rather than a global CRO with a local office, an Asia medical consultant suggests
You may also be interested in...
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).